Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo

Zhang,Haiping; Sui,Aihua; Wang,Zhenli; Liu,Shihai; Yao,Ruyong

doi:10.3892/ijmm.2012.998

Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo

Authors:
- Haiping Zhang
- Aihua Sui
- Zhenli Wang
- Shihai Liu
- Ruyong Yao
View Affiliations

Affiliations: Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, P.R. China, Central Laboratory, The Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, P.R. China, Department of Pharmacology, The First Sanatorium of Jinan Military District, Qingdao 266001, P.R. China
Published online on: May 14, 2012 https://doi.org/10.3892/ijmm.2012.998
Pages: 358-364

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary or acquired resistance to current treatment methods remains a major factor in clinical oncology and may be caused by failures in apoptosis programs. TNF-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in several human cancer cell types. However, not all cancer cells are susceptible to TRAIL and mechanisms of resistance and new strategies to enhance sensitivity are an area of intense investigation. Therefore, we investigated whether TRAIL resistance is due to Bcl-2 levels. In this study, we generated an adenoviral vector, Ad5.TRAIL/siBcl2, that permitted co-expression of shRNA against Bcl-2 and the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapeutic gene from a cytomegalovirus promoter. Infection with Ad5.TRAIL/siBcl2 resulted in significant cytotoxicity in non-small cell lung cancer (NSCLC) cells in vitro. In contrast, it had no effect on a normal lung cell line, WI-38. Impressively, treatment of the established NSCLC tumor model with Ad5.TRAIL/siBcl2 resulted in significant tumor regression, compared with other adenoviruses. This potent antitumor activity induced by Ad5.TRAIL/siBcl2 was due to strong inhibition of Bcl-2 and high expression of TRAIL. Thus, this study may provide a framework for future clinical applications of Ad5.TRAIL/siBcl2 in lung tumor gene therapy.

View Figures

View References

1.	A JemalR SiegelJ XuE WardCancer statistics, 2010CA Cancer J Clin60277300201010.3322/caac.20073
2.	L HouwenState of the art: lung cancer in ChinaAnn Thorac Cardiovasc Surg9147148200312882182
3.	DM vanHE Karim-KosS SieslingProgress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 yearsJ Thorac Oncol7291298201222157366
4.	MA BareschinoC SchettinoA RossiTreatment of advanced non small cell lung cancerJ Thorac Dis3122133201122263075
5.	BS NairV BhanderiSH JafriCurrent and emerging pharmacotherapies for the treatment of relapsed small cell lung cancerClin Med Insights Oncol5223234201121836818
6.	A AshkenaziRC PaiS FongSafety and antitumor activity of recombinant soluble Apo2 ligandJ Clin Invest104155162199910.1172/JCI692610411544
7.	JC SoriaE SmitD KhayatPhase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancerJ Clin Oncol2815271533201010.1200/JCO.2009.25.484720159815
8.	G PanRK OAM ChinnaiyanThe receptor for the cytotoxic ligand TRAILScience276111113199710.1126/science.276.5309.1119082980
9.	H WalczakMA Degli-EspostiRS JohnsonTRAIL-R2: a novel apoptosis-mediating receptor for TRAILEMBO J1653865397199710.1093/emboj/16.17.53869311998
10.	SA MarstersJP SheridanRM PittiA novel receptor for Apo2L/TRAIL contains a truncated death domainCurr Biol710031006199710.1016/S0960-9822(06)00422-29382840
11.	JG EmeryP McDonnellMB BurkeOsteoprotegerin is a receptor for the cytotoxic ligand TRAILJ Biol Chem2731436314367199810.1074/jbc.273.23.143639603945
12.	Y ZhangJH WangQ LuYJ WangBag3 promotes resistance to apoptosis through Bcl-2 family members in non-small cell lung cancerOncol Rep1109113201121971866
13.	G KroemerThe proto-oncogene Bcl-2 and its role in regulating apoptosisNat Med3614620199710.1038/nm0697-6149176486
14.	TS GriffithDH LynchTRAIL: a molecule with multiple receptors and control mechanismsCurr Opin Immunol10559563199810.1016/S0952-7915(98)80224-09794836
15.	LL CarrJH FiniganJA KernEvaluation and treatment of patients with non-small cell lung cancerMed Clin North Am9510411054201110.1016/j.mcna.2011.08.00122032426
16.	BD DalyRJ CerfolioMJ KrasnaRole of surgery following induction therapy for stage III non-small cell lung cancerSurg Oncol Clin N Am20721732201110.1016/j.soc.2011.07.00621986268
17.	MH ColemanR BuenoRole of adjuvant chemotherapy in NSCLC (stages I to III)Surg Oncol Clin N Am20757767201110.1016/j.soc.2011.07.01121986270
18.	A AshkenaziTargeting death and decoy receptors of the tumour-necrosis factor superfamilyNat Rev Cancer2420430200210.1038/nrc82112189384
19.	EE McGrathThe tumor necrosis factor-related apoptosis-inducing ligand and lung cancer: still following the right TRAIL?J Thorac Oncol6983987201110.1097/JTO.0b013e318217b6c821623278
20.	AJ BridgeS PebernardA DucrauxAL NicoulazR IggoInduction of an interferon response by RNAi vectors in mammalian cellsNat Genet34263264200310.1038/ng117312796781
21.	JE CaretteRM OvermeerFH SchagenConditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cellsCancer Res6426632667200410.1158/0008-5472.CAN-03-353015087375
22.	SH KaufmannWC EarnshawInduction of apoptosis by cancer chemotherapyExp Cell Res2564249200010.1006/excr.2000.483810739650
23.	A GrossJM McDonnellSJ KorsmeyerBcl-2 family members and the mitochondria in apoptosisGenes Dev1318991911199910.1101/gad.13.15.189910444588
24.	B JansenU Zangemeister-WittkeAntisense therapy for cancer - the time of truthLancet Oncol3672683200210.1016/S1470-2045(02)00903-812424069
25.	S CoryJM AdamsThe Bcl-2 family: regulators of the cellular life-or-death switchNat Rev Cancer2647656200210.1038/nrc88312209154